Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings.
暂无分享,去创建一个
M. Hughes | R. Gross | J. Mellors | A. Collier | J. Ritz | B. Grinsztejn | C. Godfrey | P. Mugyenyi | E. Hogg | C. Wallis | R. Salata | R. Viana | R. Mngqibisa | S. Saravanan | Linda Wieclaw | M. Van Schalkwyk | L. Hovind | C. S. de Jesus
[1] T. F. Rinke de Wit,et al. HIV drug resistance in low-income and middle-income countries. , 2018, The lancet. HIV.
[2] R. Shapiro,et al. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.
[3] J. Mellors,et al. Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low‐ and Middle‐Income Countries , 2017, The Journal of infectious diseases.
[4] T. F. Rinke de Wit,et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. , 2016, The Journal of infectious diseases.
[5] J. Mellors,et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. , 2016, The lancet. HIV.
[6] P. Easterbrook,et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. , 2014, The New England journal of medicine.
[7] Richard D Moore,et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. , 2013, The Journal of clinical investigation.
[8] D. Cooper,et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio , 2013, The Lancet.
[9] J. Vingerhoets,et al. Similar Predictions of Etravirine Sensitivity Regardless of Genotypic Testing Method Used: Comparison of Available Scoring Systems , 2012, Antiviral therapy.
[10] Monique Nijhuis,et al. Human Immunodeficiency Virus gag and protease: partners in resistance , 2012, Retrovirology.
[11] Kenneth A. Freedberg,et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial , 2012, AIDS.
[12] J. Mellors,et al. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa , 2010, AIDS research and treatment.
[13] Ian Sanne,et al. Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.
[14] Eoin Coakley,et al. A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism , 2007, PLoS medicine.
[15] Tommy F. Liu,et al. Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] R. Elston,et al. Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro , 2002, Journal of Virology.
[17] Hsinyi Tsang,et al. Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors* , 2002, The Journal of Biological Chemistry.
[18] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.